NASDAQ:BNTC Benitec Biopharma (BNTC) Stock Price, News & Analysis $9.40 +0.27 (+2.96%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$9.25▼$9.7150-Day Range$6.30▼$10.4752-Week Range$1.86▼$10.88Volume13,317 shsAverage Volume54,730 shsMarket Capitalization$88.08 millionP/E RatioN/ADividend YieldN/APrice Target$19.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Benitec Biopharma alerts: Email Address Benitec Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.25 Rating ScoreUpside/Downside109.2% Upside$19.67 Price TargetShort InterestHealthy3.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.83Based on 16 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.56) to ($2.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.18 out of 5 starsMedical Sector366th out of 936 stocksPharmaceutical Preparations Industry172nd out of 436 stocks 3.6 Analyst's Opinion Consensus RatingBenitec Biopharma has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBenitec Biopharma has only been the subject of 3 research reports in the past 90 days.Read more about Benitec Biopharma's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.73% of the float of Benitec Biopharma has been sold short.Short Interest Ratio / Days to CoverBenitec Biopharma has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Benitec Biopharma has recently decreased by 9.97%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBenitec Biopharma does not currently pay a dividend.Dividend GrowthBenitec Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNTC. Previous Next 3.2 News and Social Media Coverage News SentimentBenitec Biopharma has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Benitec Biopharma this week, compared to 1 article on an average week.Search Interest9 people have searched for BNTC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Benitec Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Benitec Biopharma is held by insiders.Percentage Held by Institutions52.19% of the stock of Benitec Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Benitec Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Benitec Biopharma are expected to grow in the coming year, from ($6.56) to ($2.35) per share.Price to Book Value per Share RatioBenitec Biopharma has a P/B Ratio of 78.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Benitec Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agency5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades About Benitec Biopharma Stock (NASDAQ:BNTC)Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Read More BNTC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNTC Stock News HeadlinesJuly 24 at 7:20 AM | americanbankingnews.comBenitec Biopharma Inc. (NASDAQ:BNTC) to Post FY2024 Earnings of ($5.45) Per Share, Leerink Partnrs ForecastsJuly 23 at 3:38 PM | markets.businessinsider.comBuy Rating on Benitec Biopharma: Anticipating BB-301’s Impact on OPMD Treatment and Stock ValueJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 23 at 3:38 PM | msn.comLeerink Partners Initiates Coverage of Benitec Biopharma (BNTC) with Outperform RecommendationJuly 23 at 6:18 AM | americanbankingnews.comBenitec Biopharma (NASDAQ:BNTC) Rating Increased to Strong-Buy at Leerink PartnrsJuly 22, 2024 | lse.co.ukBenitec Biopharma Share Price (BNTC.US)July 22, 2024 | americanbankingnews.comSVB Leerink Initiates Coverage on Benitec Biopharma (NASDAQ:BNTC)July 19, 2024 | investing.comBenitec Biopharma Ltd ADR (BNTC)July 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 19, 2024 | americanbankingnews.comBenitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above 50 Day Moving Average of $8.33July 15, 2024 | globenewswire.comBenitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a StudyMay 20, 2024 | markets.businessinsider.comBuy Rating for Benitec Biopharma on Promising Early-Stage Clinical Data and Solid FinancialsMay 13, 2024 | finance.yahoo.comBenitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational UpdateMay 13, 2024 | investorplace.comBNTC Stock Earnings: Benitec Biopharma Misses EPS for Q3 2024May 1, 2024 | finance.yahoo.comBenitec Biopharma to Participate in the Citizens JMP Life Science ConferenceApril 18, 2024 | msn.comWhy Is Gene Therapy Developer Benitec Biopharma Stock Trading Higher On Thursday?April 18, 2024 | finanznachrichten.deBenitec Biopharma Inc.: Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a StudyApril 18, 2024 | msn.comBenitec Biopharma jumps 33% on $40M private financingSee More Headlines Receive BNTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)9/19/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BNTC CUSIPN/A CIK1808898 Webwww.benitec.com Phone510-780-0819Fax61 (0)3 9966-9923Employees16Year FoundedN/APrice Target and Rating Average Stock Price Target$19.67 High Stock Price Target$30.00 Low Stock Price Target$13.00 Potential Upside/Downside+109.2%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,560,000.00 Net MarginsN/A Pretax Margin-309,885.78% Return on Equity-175.36% Return on Assets-127.85% Debt Debt-to-Equity Ratio0.01 Current Ratio4.18 Quick Ratio4.18 Sales & Book Value Annual Sales$80,000.00 Price / Sales1,100.98 Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book78.33Miscellaneous Outstanding Shares9,370,000Free Float8,965,000Market Cap$88.08 million OptionableNo Data Beta0.91 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Jerel A. Banks M.D. (Age 49)Ph.D., Executive Chairman & CEO Comp: $848.07kMs. Megan Joan Boston BComm (Age 52)CA, Dip., GAICD, Executive Director Comp: $439.17kDr. Michael GrahamHead of Discovery & Founding ScientistDr. Claudia KlothSenior Vice President of ManufacturingKey CompetitorsAC ImmuneNASDAQ:ACIUKamadaNASDAQ:KMDAInozyme PharmaNASDAQ:INZYNkartaNASDAQ:NKTXXOMANASDAQ:XOMAView All CompetitorsInstitutional OwnershipGAMMA Investing LLCBought 1,884 shares on 7/2/2024Ownership: 0.058%Janus Henderson Group PLCBought 64,092 shares on 5/16/2024Ownership: 9.440%View All Institutional Transactions BNTC Stock Analysis - Frequently Asked Questions How have BNTC shares performed this year? Benitec Biopharma's stock was trading at $3.23 at the beginning of the year. Since then, BNTC stock has increased by 191.0% and is now trading at $9.40. View the best growth stocks for 2024 here. How were Benitec Biopharma's earnings last quarter? Benitec Biopharma Inc. (NASDAQ:BNTC) announced its earnings results on Monday, May, 13th. The biotechnology company reported ($1.64) earnings per share for the quarter. When did Benitec Biopharma's stock split? Shares of Benitec Biopharma reverse split on the morning of Wednesday, July 26th 2023. The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did Benitec Biopharma IPO? Benitec Biopharma (BNTC) raised $0 in an IPO on Thursday, August 6th 2015. The company issued 0 shares at a price of $0.00 per share. BMO Capital Markets and Maxim Group LLC served as the underwriters for the IPO and Roth Capital Partners was co-manager. Who are Benitec Biopharma's major shareholders? Benitec Biopharma's top institutional shareholders include GAMMA Investing LLC (0.06%). View institutional ownership trends. How do I buy shares of Benitec Biopharma? Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Benitec Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX) and AVEO Pharmaceuticals (AVEO). This page (NASDAQ:BNTC) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Benitec Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
